SIETES :: 93213 citas

Resultados de la búsqueda por FACTOR DE NECROSIS TUMORAL ALFA REFINAR BÚSQUEDA

1.

French JB, Bonacini M, Ghabril M, Foureau D, Bonkovsky HL. Hepatotoxicity associated with the use of anti-TNF-a agents. Drug Saf 2016;39:199-208. [Ref.ID 100140]

2.

Anónimo. adalimumab (Humira) et enfants atteints de maladie de Crohn sévère. Autant d'incertitudes qu'avec l'infliximab. Prescrire 2014;34:98. [Ref.ID 97124]

3.

Simon PC, Vallano A. Fármacos que inhiben el factor de necrosis tumoral alfa y embarazo. Med Clin (Barc) 2013;141:257-9. [Ref.ID 96078]

4.

Aubin F, Carbonnel F, Wendling D. The complexity of adverse side-effects to biological agents. Journal of Crohn's and Colitis 2013;7:257-62. [Ref.ID 96072]

5.

Dixon W, Felson DT. Is anti-TNF therapy safer than previously throught?. JAMA 2011;306:2331. [Ref.ID 91687]

6.

Grijalva CG, Chen L, Baddley JW, Beukelman T, Winthrop KL, Griffin MR, Herrinton LJ, Ouellet-Hellstrom R, Patkar NM, Solomon DH, Lewis JD, Xie F, Saag KG, Curtis JR. Initiation of tumor necrosis factor-alfa antagonists and the risk of hospitalization for infection in patients with autoimmune diseses. JAMA 2011;306:2331-9. [Ref.ID 91686]

7.

Pérez-Sola MJ, Torre-Cisneros J, Pérez-Zafrilla B, Carmona L, Descalzo MA, Gómez-Reino JJ. Infecciones en pacientes tratados con antagonistas del factor de necrosis tumoral: incidencia, etiología y mortalidad en el registro BIOBADASER. Med Clin (Barc) 2011;137:533-40. [Ref.ID 91581]

8.

Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctôt KL. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67:446-57. [Ref.ID 88168]

9.

Anónimo. Information for Healthcare Professionals: Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi). FDA 2009:4 agosto. [Ref.ID 86465]

10.

Anónimo. Certolizumab pégol. Maladie de Crohn en dernier recours: en rester aux autres anti-TNF alpha. Prescrire 2009;29:95. [Ref.ID 85220]

11.

Anónimo. Certolizumab (Cimzia) for Crohn's disease. Med Lett Drugs Ther 2008;50:81-2. [Ref.ID 84441]

12.

Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, Colombel JF. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet 2008;372:67-81. [Ref.ID 83496]

13.

Tanne JH. Drugs for rheumatoid arthritis may have heart benefits. BMJ 2008;336:580. [Ref.ID 82377]

14.

Dudzinski DM, Kesselheim AS. Scientific and legal viability of follow-on protein drugs. N Engl J Med 2008;358:843-9. [Ref.ID 82210]

15.

List AF. Lenalidomide - The phoenix rises. N Engl J Med 2007;357:2183-6. [Ref.ID 81605]

16.

Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD, for the Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-42. [Ref.ID 81602]

17.

Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San MIguel J, Hellmann A, Facon T, Foà R, Corso A, Masliak Z, Olesnychyj M, Yu Z, Patrin J, Zeldis JB, Knight RD, for the Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-32. [Ref.ID 81601]

18.

Lewis JD. Anti-TNF antibodies for Crohn's disease. The editorialist replies. N Engl J Med 2007;357:1662. [Ref.ID 81311]

19.

Camilleri M. Anti-TNF antibodies for Crohn's disease. N Engl J Med 2007;357:1662. [Ref.ID 81310]

20.

Emery P, Kvien TK. Treating rheumatoid arthritis. BMJ 2007;335:56-7. [Ref.ID 80714]